Tag : SMART-CHOICE 3 TRIAL

CONFERENCE UPDATE

Long-term clopidogrel monotherapy superior to aspirin in high ischemic risk patients post-PCI: Results from the SMART-CHOICE 3 trial
The SMART-CHOICE 3 trial reveals that long-term clopidogrel monotherapy significantly reduces the risk of major adverse cardiac and cerebrovascular events compared to aspirin in high-risk patients following percutaneous coronary intervention (PCI), suggesting clopidogrel may be a superior treatment option for this population.